Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Repair credits look generous on paper, especially when you are exhausted from negotiations and eager to get to closing. Once ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

The FDA-approved Agilent MMR IHC Panel pharmDx identifies dMMR tumors in colorectal cancer, guiding immunotherapy treatment with nivolumab and ipilimumab. dMMR tumors, characterized by high mutation ...

aDepartment of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, China bGuangdong Provincial Key Laboratory of Precision Medicine for ...

The first-known observations of matter–antimatter asymmetry in a decaying composite subatomic particle that belongs to the baryon class are reported from the LHCb experiment located at the Large ...

1 School of Life Sciences, Jiangsu University, Zhenjiang, China 2 Department of Implantology and Prosthodontics, Zhenjiang Stomatological Hospital, Zhenjiang, China DNA polymerase delta (Pol δ) is a ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...

Please provide your email address to receive an email when new articles are posted on . Patients with stage III deficient mismatch repair colon cancer derived significant benefit from the addition of ...

Tecentriq plus chemotherapy reduced recurrence or death risk by 50% in stage III colorectal cancer with deficient mismatch repair. The combination therapy achieved a 3-year disease-free survival rate ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...